A Phase I/II Randomized, Double-blind, Positive-controlled Dose-exploration Study to Evaluate the Safety and Immunogenicity of a Virus-like Particle (VLP) Based Vaccine Against Poliomyelitis (VLP-Polio) in Infants From 6 Weeks of Age and Toddlers 12-18 Months of Age
Latest Information Update: 03 Sep 2024
Price :
$35 *
At a glance
- Drugs Recombinant trivalent poliomyelitis vaccine Tianjin CanSino Biotechnology (Primary) ; Poliovirus vaccine inactivated
- Indications Poliomyelitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Tianjin CanSino Biotechnology
- 03 Sep 2024 New trial record